Trial Condition(s):

QTc evaluation, Electrocardiography

Influence of moxifloxacin on QTc interval in healthy subjects for positive control validation

Bayer Identifier:

13796

ClinicalTrials.gov Identifier:

NCT01014247

EudraCT Number:

2009-012363-34

Study Completed

Trial Purpose

The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study).

Inclusion Criteria
- Healthy volunteers  
 - Age 18-75 years - Normal ECG
Exclusion Criteria
- Abnormal ECG - Intolerance to fluorochinolones

Trial Summary

Enrollment Goal
56
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
Yes
Products
Avelox (Moxifloxacin hydrochloride, BAY12-8039)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Medizinische Fakultät Carl Gustav Carus

Dresden, Germany, 01307

Status
Completed
 
Locations

Universitätsklinikum Giessen und Marburg

Gießen, Germany, 35392

Status
Completed
 
Locations

Nucleus Network Ltd

Melbourne, Australia, 3004

Status
Completed
 
Locations

National University Hospital

Singapore , Singapore, 119228

Status
Completed
 
Locations

National Heart Centre

Singapore, Singapore, 168752

Status
Completed
 
Locations

Hammersmith Hospital

London, United Kingdom, W12 0HS

Status
Terminated
 

Trial Design